Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

Solid Tumor Targeting CAR-T Development Service: Preventing Antigen Stripping

Q: How do you validate Armored CAR-T cells?

We test them in immunosuppressive in vitro models, confirming enhanced cytokine secretion, sustained proliferation, and tumor-killing ability versus non-armored controls.

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Related Services Contact

Creative Biolabs provides a next-generation solid tumor targeting CAR-T Development Service, designed to overcome challenges such as diminished efficacy caused by trogocytosis, antigen escape, and off-target toxicity. By leveraging advanced multi-antigen targeting strategies (TanCARs) and proprietary affinity-tuning platforms, we enable the creation of CAR-T cells with enhanced potency, specificity, and safety. Our integrated approach empowers researchers to achieve durable anti-tumor responses and effectively navigate the immunosuppressive and hostile microenvironments of solid tumors.

Introduction

CAR-T therapy has achieved success in blood cancers but faces significant challenges in solid tumors. Key obstacles include the scarcity of true tumor-specific antigens (TSAs), the risk of "on-target, off-tumor" toxicity from targeting tumor-associated antigens (TAAs), and trogocytosis—where CAR-T cells remove the target antigen, leading to their own exhaustion and tumor relapse.

CAR-T cells ingest surface antigens from tumor cells through phagocytosis. (OA Literature) Fig.1 CAR-T cells take in tumor cell surface antigens via phagocytosis.¹

Service

Creative Biolabs mitigates antigen stripping (trogocytosis) and single-antigen escape by designing multi-targeted CAR constructs that retain functional avidity, even when the primary target is lost. Furthermore, we eliminate the primary risk associated with solid tumor TAAs by optimizing CAR design to maximize tumor-killing precision while ensuring healthy tissues remain untouched.

Trogocytosis-Resistant CAR Constructs: Delivery of novel Tandem CAR (TanCAR) or Dual-CAR vector designs that maintain T-cell activation even if one target antigen is stripped or downregulated.
Safety-Enhanced T-Cell Lines: Production of affinity-tuned CAR-T cells, validated to exhibit low or negligible "on-target, off-tumor" toxicity against TAA-expressing healthy cell lines.
Potency against Hostile TME: Customized Armored CAR-T cell lines engineered to secrete immune-boosting cytokines or to be genetically insensitive to immunosuppressive factors, thereby sustaining activity in the dense solid tumor microenvironment.
Comprehensive Data Package: A detailed report confirming CAR expression, in vitro cytotoxicity, cytokine release profile, and antigen-stripping resistance metrics.

Discover How We Can Help - Request a Consultation Today to engineer precision and durability into your next-generation cell therapy project.

What We Can Offer

Creative Biolabs leverages decades of expertise in immunology and genetic engineering to deploy advanced platforms specifically designed to address the antigen escape, antigen stripping, and safety limitations inherent to solid tumor CAR-T development.

Antigen Escape Prevention
Tandem CARs target two antigens with a single receptor ("OR" logic). Dual CARs co-express two separate CARs on the T cell.
CAR Affinity-Tuning
We optimize CAR binding affinity to activate only against tumor cells with high antigen density, sparing healthy tissues and reducing "on-target, off-tumor" toxicity.
Microenvironment Reprogramming
Armored CARs: These fourth-generation CARs are engineered to secrete cytokines to counteract the immunosuppressive tumor microenvironment, enhancing T-cell persistence and function.

Our Workflow

Workflow of CAR-T Development by Preventing Antigen Stripping. (Creative Biolabs Original)

Advantages

Proprietary Affinity-Tuning Platform

We systematically optimize CAR binding affinity to enable selective tumor recognition, thereby reducing the risk of "on-target, off-tumor" toxicity associated with high-affinity scFvs.

Expertise in Multi-Targeting CARs

We specialize in designing complex Tandem and Armored CARs that resist both antigen escape and the immunosuppressive TME.

Validated Resistance to Trogocytosis

Using specialized assays, we quantitatively confirm each CAR-T product's resistance to antigen stripping, ensuring sustained anti-tumor activity.

FAQs

How do you mitigate "on-target, off-tumor" toxicity?

We engineer CAR scFvs for optimal (not maximal) affinity, enabling selective activation only on tumor cells with high antigen density, sparing healthy tissues.

How do you validate Armored CAR-T cells?

We test them in immunosuppressive in vitro models, confirming enhanced cytokine secretion, sustained proliferation, and tumor-killing ability versus non-armored controls.

Can you address tumors with heterogeneous antigen expression?

Yes. Our Tandem or Dual CAR strategies target multiple antigens simultaneously, ensuring efficacy even when tumor cells express different targets.

Related Services

CAR-T Development by Epigenetic/Pharmacologic Antigen Modulation

Creative Biolabs enhances CAR-T performance for solid tumors by applying epigenetic and pharmacologic strategies to upregulate tumor antigen expression. Through selective small-molecule modulation and chromatin remodeling approaches, we increase target density, improve CAR-T recognition, and strengthen antitumor activity against heterogeneous or low-antigen tumors.

Dual/Tandem CAR Development

Creative Biolabs develops dual and tandem CAR designs to address antigen heterogeneity and escape in solid tumors. By enabling simultaneous recognition of multiple tumor antigens and optimizing cooperative signaling, our engineered CAR-T cells achieve improved specificity, stronger cytotoxicity, and more durable antitumor responses in complex tumor microenvironments.

Partner with Us

Creative Biolabs is your expert partner in next-generation cell therapy, specifically engineered to overcome the persistent challenges of solid tumor targeting and relapse. Our Solid Tumor Targeting CAR-T Development Service delivers robust, safety-enhanced, and antigen-stripping-resistant cellular products via our proprietary affinity-tuning and multi-targeting platforms. We provide the scientific rigor and validated data necessary to move your innovative therapy from concept to clinic with confidence. To discuss your specific project needs and learn how our customized CAR-T solutions can accelerate your therapeutic goals, please reach out to our specialist team.

Reference

Miao, Lele et al. "Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors." Frontiers in immunology vol. 12 687822. 19 May. 2021. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2021.687822

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.